Compare RGCO & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | STXS |
|---|---|---|
| Founded | 1912 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.9M | 210.0M |
| IPO Year | N/A | 2004 |
| Metric | RGCO | STXS |
|---|---|---|
| Price | $22.50 | $2.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 8.8K | ★ 615.6K |
| Earning Date | 11-19-2025 | 11-11-2025 |
| Dividend Yield | ★ 3.62% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $95,334,212.00 | $30,075,000.00 |
| Revenue This Year | $9.00 | $24.48 |
| Revenue Next Year | $8.30 | $29.98 |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | 12.63 | ★ 19.62 |
| 52 Week Low | $19.06 | $1.54 |
| 52 Week High | $23.82 | $3.59 |
| Indicator | RGCO | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 57.28 | 44.02 |
| Support Level | $21.86 | $2.34 |
| Resistance Level | $22.42 | $2.46 |
| Average True Range (ATR) | 0.59 | 0.11 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 75.37 | 56.67 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.